High cure rate with standardised short-course multidrugresistant tuberculosis treatment in Niger: No relapses

International Journal of Tuberculosis and Lung Disease

Volumn 18, Issue 10, 2014, Pages 1188-1194

  Piubello, A ^a   Harouna, S Hassane ^a   Souleymane, M B ^a   Boukary, I ^a   Morou, S ^a   Daouda, M ^a   Hanki, Y ^b   Van Deun, A ^c,d  

^a Damien Foundation   (Niger)

^b Niger Republic   (Niger)

^c INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^d INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

Fluoroquinolones; MDR TB; Niger

Indexed keywords

ANTIEMETIC AGENT; CLOFAZIMINE; ETHAMBUTOL; GATIFLOXACIN; ISONIAZID; KANAMYCIN; OFLOXACIN; ORAL ANTIDIABETIC AGENT; PROTIONAMIDE; PYRAZINAMIDE; STREPTOMYCIN; DRUG COMBINATION; QUINOLONE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTHRALGIA; ARTICLE; BACTERIUM CULTURE; BODY MASS; CLINICAL TRIAL; COHORT ANALYSIS; DEPRESSION; DIAGNOSTIC TEST; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTRITIS; HEARING IMPAIRMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; KIDNEY DISEASE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; NIGER; NONHUMAN; OPTIC NEURITIS; OTOTOXICITY; PATIENT MONITORING; PERIPHERAL NEUROPATHY; PROGRAM EFFECTIVENESS; PROSPECTIVE STUDY; SHORT COURSE THERAPY; SKIN DISCOLORATION; SKIN PIGMENTATION; SPUTUM SMEAR; STANDARDIZATION; VOMITING; YOUNG ADULT; BODY WEIGHT; DOSE RESPONSE; DRUG COMBINATION; HIV INFECTIONS; MULTIDRUG RESISTANCE; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ADOLESCENT; ADULT; AGED; BODY MASS INDEX; BODY WEIGHT; CLOFAZIMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ETHAMBUTOL; FEMALE; FLUOROQUINOLONES; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; KANAMYCIN; MALE; MIDDLE AGED; NIGER; PROSPECTIVE STUDIES; PYRAZINAMIDE; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84907033159     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.13.0075     Document Type: Article

References (31)

1. World Health Organization Global tuberculosis report, 2013 WHO/HTM/TB/2013.11 Geneva, Switzerland: WHO, 2013.
2. World Health Organization Guidelines for the programmatic management of drug-resistant tuberculosis-2011 update WHO/HTM/TB/2011.6 Geneva, Switzerland: WHO, 2011.
3. Ahuja S D, Ashkin D, Ave ndano M, et al Multidrug-resistant pulmonary tuberculosis treatment regimens and patients outcomes: an individual patient data meta-analysis of 9,153 patients PLOS MED 2012; 9: e1001300.
4. Van Deun A, Maug A K J, Hamid SalimMA, et al Short, highly effective and inexpensive standardized treatment of multidrugresistant tuberculosis Am J Respir Crit Care Med 2010; 182: 684-692.
5. Joint Unite d Nations Programme on HIV/AIDS UNAIDS Report on the Global AIDS epidemic 2013 UNAIDS JC2502/1/E Geneva, Switzerland: UNAIDS, 2013.
6. World Health Organization Guidelines for the programmatic management of drug resistant tuberculosis-emergency update 2008 WHO/HTM/TB/2008.402 Geneva, Switzerland: WHO, 2008.
7. Johnson J L, Hadad D J, Boom W H, et al Early and extended early bactericidal activity of levof loxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis Int J Tuberc Lung Dis 2006; 10: 605-612.
8. Hu Y, Coates A R, Mitchison D A.Sterilizing activities of fluoroquinolones against rifamp in-tolerant populations of Mycobacterium tuberculosis Antimicrob Agents Chemother 2003; 47: 653-657.
9. Rustomjee R, Lienhardt C, Kanyok T, et al A Phase II study of the sterilising activities o f ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis Int J Tuberc Lung Dis 2008; 12: 128-138.
10. Ginsburg A S, Grosset J H, Bishai W R.Fluoroquinolones, tuberculosis, and resistance Lancet Infect Dis 2003; 3: 432-442.
11. Van der Heijden Y F, Maruri F, Blackman A, et al Fluoroquinolone susceptibility in Mycobacterium tuberculosis after pre-diagnosis exposure to older-versu s newer-generation fluoroquinolones Int J Antimicrob Agents 2013; 42: 232-237.
12. Chang K C, Leung C C, Yew W W, et al Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-res istant tuberculosis Antimicrob Agents Chemother 2012; 56: 5465-5475.
13. Barry V C, Belton J G, Conalty M L, et al A new series of phenazines (rimino-compounds) with high antituberculosis activity Nature (London) 1957; 179: 1013-1015.
14. Reddy V M, Nadadhur G, Daneluzzi D, O'Sullivan J F, Gangadharam P R.Anti-tuberculosis activities of clofazimine and its new analogs B4154 and B4157 Antimicrob Agents Chemother 1996 40, 633-636.
15. Gopal M, Padayatchi N, Metcalfe J Z, O'Donnell M R.Systematic review of clofazimine for the treatment of drugresistant tuberculosis Int J Tuberc Lung Dis 2013; 17: 1001-1007.
16. Grosset J H, Tyagi S, Almeida D V, et al Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice Am J Respir Crit Care Med 2013; 188: 608-612.
17. Madison B, Robinson-Dunn B, George I, et al Multicenter evaluation of ethambutol susceptibility testing of Mycobacterium tuberculosis by agar proportion and radiometric methods J Clin Microbiol 2002; 40: 3976-3979.
18. Katiyar S K, Bihari S, Prakash S, Mamtani M, Kulkarni H.A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis Int J Tuberc Lung Dis 2008; 12: 139-145.
19. Schaaf H S, Victor T C, Venter A, et al Ethionamide cross-and co-resistance in children with isoniazid-resistant tuberculosis Int J Tuberc Lung Dis 2009; 13: 1355-1359.
20. Victor T C,Warren R, Butt J L, et al Genome and MIC stability in Mycobacterium tuberculosis and indications for continuation of use of isoniazid in multidrug-resistant tuberculosis J Med Microbiol 1997; 46: 847-857.
21. Abate G, Höffner S E, Thomsen V O, Miörner H.Characterization of isoniazid-resistant strains of Mycobacterium tuberculosis on the basis of phenotypic properties and mutations in katG Eur J Clin Microbiol Infe ct Dis 2001; 20: 329-333.
22. Van Deun A, Salim M A, Das A P, Bastian I, Portaels F.Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh Int J Tuberc Lung Dis 2004; 8: 560-567.
23. Holtz T H, Sternberg M, Kammerer S, et al Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome Ann Inter n Med 2006; 144: 650-659.
24. Nathanson E, Lambregts-van Weezenbeek C, Rich M L, et al Multidrug-resistant tuberculosis management in resourcelimited settings Emerg Infect Dis 2006; 12: 1389-1397.
25. Monedero I, Caminero J A.Common errors in multidrugresistant tuberculosis management Expert Rev Respir Med 2014; 8: 15-23.
26. Tang S, Tan S, Yao L, et al Risk factors for poor treatment outcomes in patients with MDR-TB and XDR-TB in China: retrospective multi-center investigation PLOS ONE 2013; 8: e82943.
27. Kurbatova E V, Taylor A, Gam mino V M, et al Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects Tuberculosis (Edinb) 2012; 92: 397-403.
28. Shin S S, Pasechnikov A D, Gelmanova I Y, et al Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia Int J Tuberc Lung Dis 2007; 11: 1314-1320.
29. Sagwa E, Mantel-Teeuwisse A K, Ruswa N, et al The burden of adverse events during treatment of drug-resistant tuberculosis in Namibia South Med Rev 2012; 5: 6-13.
30. De Jage r P, van Altena R.Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis Int J Tuberc Lung Dis 2002; 6: 622-627.
31. Seddon J A, Godfrey-Faussett P, Jacobs K, Ebrahim A, Hesseling A C, Schaaf H S.Hearing loss in patients on treatment for drug-resistant tuberculosis Eur Respir J 2012; 40: 1277-1286.